Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis.
暂无分享,去创建一个
Paul Welsh | Jennifer E Ho | Christopher P Cannon | Terje R Pedersen | M. Sabatine | E. Braunwald | C. Cannon | S. Murphy | J. D. de Lemos | P. Barter | D. Waters | J. Kastelein | D. Demicco | P. Welsh | N. Sattar | J. Ho | T. Pedersen | K. Ray | D. Preiss | S. Seshasai | Kausik K Ray | Sreenivasa Rao Kondapally Seshasai | Naveed Sattar | James A de Lemos | Marc S Sabatine | Sabina A Murphy | Eugene Braunwald | Michael A Blazing | M. Tikkanen | David Preiss | Matti J Tikkanen | John J P Kastelein | Philip Barter | M. Blazing | David D Waters | David A DeMicco
[1] P. Barter,et al. Predictors of new-onset diabetes in patients treated with atorvastatin: results from 3 large randomized clinical trials. , 2011, Journal of the American College of Cardiology.
[2] Peter H Whincup,et al. Impact of diabetes on cardiovascular disease risk and all-cause mortality in older men: influence of age at onset, diabetes duration, and established and novel risk factors. , 2011, Archives of internal medicine.
[3] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12,064 survivors of myocardial infarction: a double-blind randomised trial. , 2010, Lancet.
[4] R. Collins,et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials , 2010, The Lancet.
[5] R. Collins,et al. Intensive lowering of LDL cholesterol with 80 mg versus 20 mg simvastatin daily in 12 064 survivors of myocardial infarction: a double-blind randomised trial , 2010, The Lancet.
[6] Walter T Ambrosius,et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. , 2010, The New England journal of medicine.
[7] J. McEvoy. Statins and risk of incident diabetes , 2010, The Lancet.
[8] M. Quon,et al. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. , 2010, Journal of the American College of Cardiology.
[9] Heiner Greten,et al. Comparison of 80 versus 10 mg of atorvastatin on occurrence of cardiovascular events after the first event (from the Treating to New Targets [TNT] trial). , 2010, The American journal of cardiology.
[10] Christina Lindahl,et al. Total cardiovascular disease burden: comparing intensive with moderate statin therapy insights from the IDEAL (Incremental Decrease in End Points Through Aggressive Lipid Lowering) trial. , 2009, Journal of the American College of Cardiology.
[11] E. Braunwald,et al. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction , 2009, Journal of the American College of Cardiology.
[12] D. Moher,et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement , 2009, BMJ.
[13] Desmond E. Williams,et al. Full Accounting of Diabetes and Pre-Diabetes in the U.S. Population in 1988–1994 and 2005–2006 , 2009, Diabetes Care.
[14] F. Westwood,et al. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy , 2009, The Journal of physiology.
[15] Cholesterol Treatment Trialists' Collaborators. Efficacy of cholesterol-lowering therapy in 18 686 people with diabetes in 14 randomised trials of statins: a meta-analysis , 2008, The Lancet.
[16] R Peto,et al. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. , 2008, Lancet.
[17] P. Mitchell,et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial , 2007, The Lancet.
[18] Diederick E Grobbee,et al. Effect of rosuvastatin on progression of carotid intima-media thickness in low-risk individuals with subclinical atherosclerosis: the METEOR Trial. , 2007, JAMA.
[19] Prakash Deedwania,et al. Effects of Intensive Versus Moderate Lipid-Lowering Therapy on Myocardial Ischemia in Older Patients With Coronary Heart Disease: Results of the Study Assessing Goals in the Elderly (SAGE) , 2007, Circulation.
[20] Christopher P Cannon,et al. Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy. , 2006, Journal of the American College of Cardiology.
[21] O. Faergeman,et al. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. , 2005, JAMA.
[22] R. Collins,et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins , 2005, The Lancet.
[23] Philip J. Barter,et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. , 2005, The New England journal of medicine.
[24] D. Hunninghake,et al. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the alliance study. , 2004, Journal of the American College of Cardiology.
[25] M. Pfeffer,et al. Early Intensive vs a Delayed Conservative Simvastatin Strategy in Patients With Acute Coronary Syndromes , 2004 .
[26] Christopher P Cannon,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[27] Paul Schoenhagen,et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. , 2004, JAMA.
[28] J. LeLorier,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[29] D. Altman,et al. Measuring inconsistency in meta-analyses , 2003, BMJ : British Medical Journal.
[30] Elinor Miller,et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). , 2003, The American journal of cardiology.
[31] P W Macfarlane,et al. Pravastatin and the Development of Diabetes Mellitus: Evidence for a Protective Treatment Effect in the West of Scotland Coronary Prevention Study , 2001, Circulation.
[32] H. Vet,et al. The Delphi list: a criteria list for quality assessment of randomized clinical trials for conducting systematic reviews developed by Delphi consensus. , 1998, Journal of clinical epidemiology.
[33] Post Coronary Artery Bypass Graft Trial Investigators. The effect of aggressive lowering of low-density lipoprotein cholesterol levels and low-dose anticoagulation on obstructive changes in saphenous-vein coronary-artery bypass grafts. , 1997, The New England journal of medicine.